M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Pineros A R ^a   Campos, L W ^a   Fonseca, D M ^a   Bertolini, T B ^a   Gembre, A F ^a   Prado, R Q ^a   Alves Filho, J C ^a   Ramos, S G ^a   Russo, M ^a   Bonato, V L D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33;

ANIMAL; BACTERIAL LOAD; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; LUNG; LUNG TUBERCULOSIS; MACROPHAGE; MICROBIOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATHOLOGY; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ALLERGENS; ANIMALS; BACTERIAL LOAD; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; LUNG; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; SIGNAL TRANSDUCTION; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 85010934696     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep41240     Document Type: Article

References (62)

1. WHO. Global Tuberculosis Report. (2014).
2. Glaziou, P., Sismanidis, C., Floyd, K., Raviglione, M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med 5, a017798, doi: 10.1101/cshperspect.a017798 (2015).
3. Millard, J., Ugarte-Gil, C., Moore, D. A. Multidrug resistant tuberculosis. Bmj 350, h882, doi: 10.1136/bmj.h882 (2015).
4. Diefenbach, A., Colonna, M., Koyasu, S. Development, Differentiation, and Diversity of Innate Lymphoid Cells. Immunity 41, 354-365, doi: 10.1016/j.immuni.2014.09.005.
5. Redente, E. F. et al. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol 88, 159-168, doi: jlb.0609378 [pii] 10.1189/jlb.0609378 (2010).
6. Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178, 2249-2254 (1993).
7. Hüser, N. et al. CCR4-deficient mice show prolonged graft survival in a chronic cardiac transplant rejection model. Eur J Immunol 35, 128-138, doi: 10.1002/eji.200324745 (2005).
8. Hartl, D. et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 117, 204-211, doi: S0091-6749(05)02109-3 [pii] 10.1016/j.jaci.2005.09.023 (2006).
9. Finotto, S. et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295, 336-338, doi: 10.1126/science.1065544 (2002).
10. Ledru, E., Ledru, S., Zoubga, A. Granuloma formation and tuberculosis transmission in HIV-infected patients. Immunol Today 20, 336-337 (1999).
11. Glynn, J. R. et al. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. Aids 22, 1859-1867, doi: 10.1097/QAD.0b013e3283097cfa (2008).
12. Casanova, J. L., Abel, L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20, 581-620, doi: 10.1146/annurev.immunol.20.081501.125851 (2002).
13. Cates, E. C. et al. Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism. J Immunol 173, 6384-6392 (2004).
14. Prado, R. Q. et al. Attenuation of experimental asthma by mycobacterial protein combined with CpG requires a TLR9-dependent IFN-gamma-CCR2 signaling circuit. Clin Exp Allergy, doi: 10.1111/cea.12564 (2015).
15. Fonseca, D. M. et al. Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway. Clin Exp Allergy 42, 131-143, doi: 10.1111/j.1365-2222.2011.03845.x (2012).
16. Fonseca, D. M. et al. IFN-?-mediated efficacy of allergen-free immunotherapy using mycobacterial antigens and CpG-ODN. Immunol Cell Biol 89, 777-785, doi: 10.1038/icb.2011.9 (2011).
17. Fonseca, D. M. et al. Requirement of MyD88 and Fas pathways for the efficacy of allergen-free immunotherapy. Allergy 70, 275-284, doi: 10.1111/all.12555 (2015).
18. Christ, A. P. et al. Enhancement of Th1 lung immunity induced by recombinant Mycobacterium bovis Bacillus Calmette-Guerin attenuates airway allergic disease. Am J Respir Cell Mol Biol 43, 243-252, doi: 10.1165/rcmb.2009-0040OC (2010).
19. Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 15, 271-282, doi: 10.1038/nri3831 (2015).
20. Herrmann, J. L., Lagrange, P. H. Dendritic cells and Mycobacterium tuberculosis: which is the Trojan horse? Pathol Biol (Paris) 53, 35-40, doi: S0369811404000069 [pii] 10.1016/j.patbio.2004.01.004 (2005).
21. Potian, J. A. et al. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 208, 1863-1874, doi: 10.1084/jem.20091473 (2011).
22. Chan, J., Tanaka, K., Carroll, D., Flynn, J., Bloom, B. R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 63, 736-740 (1995).
23. Sica, A., Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122, 787-795, doi: 10.1172/jci59643 (2012).
24. Wang, Z. et al. MicroRNA 21 is a homeostatic regulator of macrophage polarization and prevents prostaglandin E2-mediated M2 generation. PLoS One 10, e0115855, doi: 10.1371/journal.pone.0115855 (2015).
25. Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99-103, doi: 10.1038/nature13489 (2014).
26. Bourlier, V. et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117, 806-815, doi: 10.1161/circulationaha.107.724096 (2008).
27. Jakubzick, C., Tacke, F., Llodra, J., van Rooijen, N., Randolph, G. J. Modulation of dendritic cell trafficking to and from the airways. J Immunol 176, 3578-3584 (2006).
28. Vermaelen, K., Pauwels, R. Accurate and simple discrimination of mouse pulmonary dendritic cell and macrophage populations by flow cytometry: methodology and new insights. Cytometry A 61, 170-177, doi: 10.1002/cyto.a.20064 (2004).
29. Liew, F. Y., Pitman, N. I., McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10, 103-110, doi: 10.1038/nri2692 (2010).
30. Stolarski, B., Kurowska-Stolarska, M., Kewin, P., Xu, D., Liew, F. Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 185, 3472-3480, doi: 10.4049/jimmunol.1000730 (2010).
31. Wills-Karp, M. et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 209, 607-622, doi: 10.1084/jem.20110079 (2012).
32. Kim, C. H. et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108, 1331-1339, doi: 10.1172/jci13543 (2001).
33. Zhang, F. et al. Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis. Ann Clin Transl Neurol 1, 307-318, doi: 10.1002/acn3.47 (2014).
34. Rankin, A. L. et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 184, 1526-1535, doi: 10.4049/jimmunol.0903306 (2010).
35. Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490, doi: 10.1016/j.immuni.2005.09.015 (2005).
36. Wallis, R. S., Hafner, R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 15, 255-263, doi: 10.1038/nri3813 (2015).
37. Chen, F. et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med 18, 260-266, doi: 10.1038/nm.2628 (2012).
38. Scanga, C. A. et al. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 69, 7711-7717, doi: 10.1128/iai.69.12.7711-7717.2001 (2001).
39. Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178, 2243-2247 (1993).
40. Achkar, J. M., Casadevall, A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13, 250-262, doi: 10.1016/j.chom.2013.02.009 (2013).
41. de Vallière, S., Abate, G., Blazevic, A., Heuertz, R. M., Hoft, D. F. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 73, 6711-6720, doi: 10.1128/IAI.73.10.6711-6720.2005 (2005).
42. Berry, M. P. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977, doi: 10.1038/nature09247 (2010).
43. Martineau, A. R. et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 117, 1988-1994, doi: 10.1172/JCI31097 (2007).
44. Martineau, A. R. et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a doubleblind randomised controlled trial. Lancet 377, 242-250, doi: 10.1016/S0140-6736(10)61889-2 (2011).
45. Medzhitov, R., Schneider, D. S., Soares, M. P. Disease tolerance as a defense strategy. Science 335, 936-941, doi: 10.1126/science.1214935 (2012).
46. Segovia-Juarez, J. L., Ganguli, S., Kirschner, D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J Theor Biol 231, 357-376, doi: 10.1016/j.jtbi.2004.06.031 (2004).
47. Hammarén, M. M. et al. Adequate Th2-type response associates with restricted bacterial growth in latent mycobacterial infection of zebrafish. PLoS Pathog 10, e1004190, doi: 10.1371/journal.ppat.1004190 (2014).
48. Garlanda, C. et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol 179, 3119-3125 (2007).
49. Yang, G., Yang, L., Wang, W., Wang, J., Xu, Z. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene, doi: 10.1016/j.gene.2015.02.065 (2015).
50. Wieland, C. W., van der Windt, G. J., Florquin, S., McKenzie, A. N., van der Poll, T. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect 11, 524-530, doi: 10.1016/j. micinf.2009.02.007 (2009).
51. Besnard, A. G. et al. IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog 11, e1004607, doi: 10.1371/journal.ppat.1004607 (2015).
52. Michelucci, A. et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci USA 110, 7820-7825, doi: 10.1073/pnas.1218599110 (2013).
53. Jamal Uddin, M. et al. IRG1 induced by heme oxygenase-1/carbon monoxide inhibits LPS-mediated sepsis and pro-inflammatory cytokine production. Cell Mol Immunol 13, 170-179, doi: 10.1038/cmi.2015.02 (2016).
54. Ricchetti, G. A., Williams, L. M., Foxwell, B. M. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol 76, 719-726, doi: 10.1189/jlb.0104046 (2004).
55. Villarreal, D. O., Weiner, D. B. IL-33 isoforms: their future as vaccine adjuvant? Expert Rev Vaccines 14, 489-492, doi: 10.1586/14760584.2015.1011135 (2015).
56. Hazlett, L. D. et al. IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 51, 1524-1532, doi: 10.1167/iovs.09-3983 (2010).
57. Hoger, S., Lykens, K., Beavers, S. F., Katz, D., Miller, T. L. Longevity loss among cured tuberculosis patients and the potential value of prevention. Int J Tuberc Lung Dis 18, 1347-1352, doi: 10.5588/ijtld.14.0242 (2014).
58. Townsend, M. J., Fallon, P. G., Matthews, D. J., Jolin, H. E., McKenzie, A. N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 191, 1069-1076 (2000).
59. Sergio, C. A., Bertolini, T. B., Gembre, A. F., Prado, R. Q., Bonato, V. L. CD11c(+ ) CD103(+ ) cells of Mycobacterium tuberculosisinfected C57BL/6 but not of BALB/c mice induce a high frequency of interferon-gamma-or interleukin-17-producing CD4(+ ) cells. Immunology 144, 574-586, doi: 10.1111/imm.12411 (2015).
60. Kunkel, E. J., Campbell, D. J., Butcher, E. C. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 10, 313-323, doi: 7800196 [pii] 10.1038/sj.mn.7800196 (2003).
61. Morais Fonseca, D. et al. Experimental tuberculosis: designing a better model to test vaccines against tuberculosis. Tuberculosis (Edinb) 90, 135-142, doi: 10.1016/j.tube.2010.01.005 (2010).
62. Li, D. et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134, 1422-1432.e1411, doi: 10.1016/j.jaci.2014.05.011 (2014).